In developing countries, two bacteria, pneumococcus and Hib, are the dominant causes of severe pneumonia in children.
The introduction of vaccines against these diseases could reduce the global burden of severe pneumonia by about half. In this week's PLoS Medicine, J. Anthony G. Scott and Mike English—researchers at the Kenya Medical Research Institute–Wellcome Trust Collaborative Research Programme, Kenya—argue that the present classification and management guidelines for childhood pneumonia are founded on the dominance of these two organisms and will rapidly become obsolete as these vaccines are introduced.
The remaining cases of pneumonia, they say, will have a wide variety of causes and will include many cases of TB and noninfectious respiratory disease. This diversity of causes will make the diagnosis, classification, and management of pneumonia much more complex and expensive in the future.
"To be relevant to future policy,” say the authors, “research in the areas of pneumonia diagnosis, classification, prevention, or management should begin to anticipate this scenario now.”
Citation: Scott JAG, English M (2008) What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med 5(4): e86.
Source: PLoS
Related stories:
Vaccinated infants well-protected against severe pneumococcal infection in Norway
In 2006, a pneumococcal vaccine (Prevenar®) was introduced in the childhood vaccination programme in Norway. Two years later, the experiences have been published in the journal
Vaccine. The results show a strong decline in serious pneumococcal infections among young children.
Combination vaccines okay for infants, study shows
A University of Rochester study brings relief to new parents who, while navigating a jam-packed childhood vaccine schedule, can expect to soothe their newborn through as many as 15 “pokes” by his or her six-month checkup.
Flu shot does not reduce risk of death
The widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny, according to researchers in Alberta. The vaccine does confer protection against specific strains of influenza, but its overall benefit appears to have been exaggerated by a number of observational studies that found a very large reduction in all-cause mortality among elderly patients who had been vaccinated.
Bacterial pneumonia caused most deaths in 1918 influenza pandemic
The majority of deaths during the influenza pandemic of 1918-1919 were not caused by the influenza virus acting alone, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Instead, most victims succumbed to bacterial pneumonia following influenza virus infection. The pneumonia was caused when bacteria that normally inhabit the nose and throat invaded the lungs along a pathway created when the virus destroyed the cells that line the bronchial tubes and lungs.
Flu vaccine may not protect seniors well
A Group Health study in the August 2 issue of The
Lancet adds fuel to the growing controversy over how well the flu vaccine protects the elderly.
Researchers use salmonella to administer vaccines
(PhysOrg.com) -- Researchers at the Biodesign Institute at Arizona State University have made a major step forward in their work to develop a biologically engineered organism that can effectively deliver an antigen in the body. The researchers report that they have been able to use live salmonella bacterium as the containment/delivery method for an antigen.
Despite vaccine, public should not get complacent about pneumococcal disease
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.
The most natural drug
In the fight against infection, the human immune system isn’t ready for a war. Vaccines push the immune system to create defenses against illness, but they take time to work. A new process developed by scientists at the Oklahoma Medical Research Foundation (OMRF) and Emory University stands to revolutionize the process.